Loading
CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, haematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases.
CIViC holds 17 clinical evidence items and 1 assertion across 9 variants, naming Cisplatin, RG7356 and Docetaxel.
In plain words · CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.
CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment.
No product in this corpus aims at CD44 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CD44: RNA tissue enhanced (salivary gland 470 nTPM); high antibody staining in 20 normal tissues; highest cancer staining head and neck cancer (3 of 3 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer, Head and neck squamous cell carcinoma, Prostate cancer, Bladder & urothelial cancer, Cervical cancer and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CD44 tissue; Open Targets ENSG00000026508 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Stamenkovic et al, Cell, 1989, "A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family". Source.
Sources: HGNC HGNC:1681 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P16070 (protein name, function text, keywords and locations (REST API)); CIViC gene CD44 (17 evidence items, 1 assertions, 9 variants; diseases: Stomach Cancer, Ovarian Cancer, Cancer, Melanoma, Colorectal Cancer and 7 more (GraphQL API, CC0))
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, haematopoiesis, inflammation and response to bacterial infection. Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases. Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signalling pathways promoting calcium mobilisation and actin-mediated cytoskeleton reorganisation essential for cell migration and adhesion. Upon interaction with LGALS9 ligand, activates downstream signalling components including LCK, ERK and MAPK to promotes NK cell activation. Location: Cell membrane; Cell projection, microvillus; Secreted (UniProt). Locus 11p13 (HGNC).
RNA: tissue enhanced (salivary gland 470 nTPM), detected in all normal tissues.
Medium: Epididymis, Kidney, Lymph node, Pancreas, Smooth muscle, Soft tissue, Spleen, Thyroid gland.
HPA CD44 tissue · HPA CD44 pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CD44" OR ABSTRACT:"CD44" OR TITLE:"CD44 molecule IN blood group" OR ABSTRACT:"CD44 molecule IN blood group" OR TITLE:"CD44 antigen" OR ABSTRACT:"CD44 antigen" OR TITLE:"MC56" OR ABSTRACT:"MC56" OR TITLE:"Pgp1" OR ABSTRACT:"Pgp1" OR TITLE:"PGP-1" OR ABSTRACT:"PGP-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD44, not a curated reading list.
Shares Intravasation & circulating tumour cells, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Proteoglycans in cancer, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Intravasation & circulating tumour cells, Prostate cancer.
Shares Intravasation & circulating tumour cells, Prostate cancer.
Shares Intravasation & circulating tumour cells, Gastric & gastro-oesophageal junction cancer, Prostate cancer, Colorectal cancer.
Shares Intravasation & circulating tumour cells, Gastric & gastro-oesophageal junction cancer.
Shares Proteoglycans in cancer, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer.